Valneva SE (VALN) Income towards Parent Company (2021 - 2026)

Valneva SE (VALN) posted quarterly Income towards Parent Company of -$27.0 million for Q1 2026, down 297.58% year-on-year from $13.6 million in Q1 2025, and up 52.68% on a QoQ basis from -$57.0 million in Q4 2025.

Valneva SE (VALN) Income towards Parent Company (2021 - 2026) Analysis & Trends

Valneva SE (VALN) has reported Income towards Parent Company for 6 consecutive years, with -$27.0 million the latest figure, recorded in Q1 2026.

  • Quarterly Income towards Parent Company fell 297.58% year-over-year to -$27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$151.4 million (down 118.64% YoY) and the FY2025 annual result came in at -$131.1 million, down 964.36% from the prior year.
  • Income towards Parent Company grew to -$27.0 million in Q1 2026 per VALN's latest filing, from -$57.0 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for VALN reached as high as $106.2 million in Q3 2022 and fell as low as -$161.5 million in Q2 2022.
  • A 5-year average of -$22.6 million and a median of -$25.0 million in 2024 frame the typical range for Income towards Parent Company.
  • Annual changes were most pronounced in 2024 — Income towards Parent Company surged 511.54% — and 2025, when it tumbled 340.45%.
  • Year by year, Income towards Parent Company stood at -$64.1 million in 2022, then jumped by 55.8% to -$28.3 million in 2023, then surged by 54.35% to -$12.9 million in 2024, then slumped by 340.45% to -$57.0 million in 2025, then soared by 52.68% to -$27.0 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$27.0 million, -$57.0 million, and -$55.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Valneva SE 839.21 Mn 719.43 Mn 5.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -26.96 Mn
Dec 31, 2025 -56.99 Mn
Sep 30, 2025 -55.04 Mn
Jun 30, 2025 -12.37 Mn
Mar 31, 2025 -6.78 Mn
Dec 31, 2024 -12.94 Mn
Sep 30, 2024 -24.99 Mn
Jun 30, 2024 -24.52 Mn
Mar 31, 2024 77.62 Mn
Dec 31, 2023 -28.34 Mn
Sep 30, 2023 -25.28 Mn
Jun 30, 2023 -20.93 Mn
Mar 31, 2023 -18.86 Mn
Dec 31, 2022 -64.12 Mn
Sep 30, 2022 106.19 Mn
Jun 30, 2022 -161.49 Mn
Mar 31, 2022 -28.49 Mn
Dec 31, 2021 192.56 Mn
Sep 30, 2021 -179.32 Mn
Jun 30, 2021 -64.44 Mn